Back to search

Article

Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial

2022-01-04

Abstract excerpt

Background: A third dose of homologous or heterologous COVID-19 vaccine is suggested to use in individuals who were previously primed with two doses of inactivated COVID-19 vaccine.<br><br>Methods: We conducted a randomised, open-label, parallel-controlled trial to evaluate the safety and immunogenicity of heterologous boost immunisation with an aerosolized adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d60d0752-9a2a-5524-9261-c3087cbaf991
DOI
10.2139/ssrn.4000565
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control TrialDOI 10.2139/ssrn.4000565
Safety, Immunogenicity and Efficacy of Heterologous Boost with an Aerosolized Ad5-nCoV after Two-Dose Priming with Inactivated COVID-19 Vaccines in Adults: A Multicenter, Open-Label TrialSemantic proximity
Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized TrialSemantic proximity
Safety and Immunogenicity of Heterologous and Homologous Boosting with Orally Aerosolized or Intramuscular Ad5-nCoV and Inactivated Vaccines in Children and Adolescents: A Randomized, Open-Label, Parallel Controlled, Single-Center StudySemantic proximity
Heterologous prime-boost immunization with CoronaVac and ConvideciaSemantic proximity
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialSemantic proximity
Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity
Immunogenicity and safety of the homogenous booster shot of a recombinant fusion protein vaccine (V-01) against COVID-19 in healthy adult participants primed with a two-dose regimenSemantic proximity
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19Semantic proximity
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccinationSemantic proximity
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination among healthcare workersSemantic proximity
Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized studySemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
Select a neighboring publication to make it the new centre.